Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company engaged in the discovery and development of novel allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer. Leveraging advanced immunotherapy techniques, Adicet Bio is pioneering the use of gamma delta T cells engineered with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to create 'off-the-shelf' therapies aimed at providing durable and effective treatments for patients.
Core Products and Pipeline:
- ADI-001: A first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, currently in a Phase 1 clinical trial for relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and autoimmune diseases such as lupus nephritis.
- ADI-270: An armored gamma delta CAR T cell product candidate targeting CD70, in preclinical development for renal cell carcinoma and other CD70+ solid and hematological malignancies.
Recent Achievements and Collaborations:
- FDA clearance of the Investigational New Drug (IND) application for ADI-001 in lupus nephritis and initiation of Phase 1 clinical trial expected in 2Q 2024.
- Strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics.
- Successful Series A financing round, raising $51 million led by Orbimed Partners, Orbimed Israel, and Novartis Ventures.
- Inducement awards granted to new employees as material inducements for employment, signifying ongoing growth and talent acquisition within the company.
- Presentation of promising preclinical data on ADI-270 at major scientific annual meetings, indicating robust anti-tumor activity and potential clinical benefits.
Financial Overview: Adicet Bio maintains a strong cash position with $247.6 million in cash and cash equivalents as of March 31, 2024, providing sufficient funding to support operations into the second half of 2026. The company continues to strategically invest in research and development, as well as in expanding its organizational capabilities.
Adicet Bio is at the forefront of innovation in the biotechnology space, striving to bring transformative therapies to patients with unmet medical needs. For more information, please visit Adicet Bio's official website.
Rhea-AI Summary
Adicet Bio, Inc. has announced a public offering of common stock and pre-funded warrants, with an expected gross proceeds of approximately $85.2 million. The offering aims to raise funds for the clinical stage biotechnology company's research and development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (ACET) has announced the commencement of an underwritten public offering of its common stock and pre-funded warrants to purchase shares of its common stock. The offering is subject to market conditions and the company's shelf registration statement previously filed with the SEC. Jefferies and Guggenheim Securities are acting as joint book-running managers for the proposed offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) aims to expand the clinical development of ADI-001 into autoimmune diseases following the clearance of the Investigational New Drug Application (IND). The company plans to initiate a Phase 1 clinical study in 2Q 2024, focusing on mantle cell lymphoma (MCL) given favorable complete response (CR) rate, durability, and safety. They also expect to submit an IND for ADI-270 in renal cell carcinoma in 2Q 2024, with an updated cash runway into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.73%
Tags
News
Rhea-AI Summary
Adicet Bio, Inc. (ACET) to Host Conference Call and Webcast Presentation to Provide Update on Clinical Pipeline and Corporate Outlook
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.73%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) granted an inducement award to a new employee, providing 84,000 non-qualified stock options at an exercise price of $1.89 per share. The options will vest over a four-year period, subject to the employee's continued employment. The award was granted outside of Adicet's stockholder-approved equity incentive plans pursuant to the Inducement Plan adopted by the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (ACET) announced encouraging observations from the pharmacokinetic and pharmacodynamic analyses of ADI-001 at the 65th ASH Annual Meeting. The data showed robust dose-dependent expansion and persistence in patients with relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma (NHL), supporting ADI-001's potential as a best-in-class allogeneic CAR T platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
ACET: Adicet Bio Reports 3rd Quarter Financial Results and Operational Highlights, Initiates Phase 1 EXPAND Cohort for ADI-001 in Post CAR T LBCL, Prioritizes ADI-270 for Solid Tumor Applications
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) will present at the 2023 Jefferies London Healthcare Conference on November 14, 2023. The presentation will be available via live audio webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) has announced the acceptance of a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. The presentation will focus on the expansion, persistence, and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR Gamma Delta T cell therapy, in patients with relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. The presentation will be given by Dr. Monica Moreno on December 10, 2023, from 6:00 - 8:00 p.m. PDT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.85%
Tags
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) has granted an inducement award to a new employee, consisting of 5,000 non-qualified stock options. The exercise price is $1.32 per share, with vesting scheduled over a four-year period. The award was granted outside of Adicet's stockholder-approved equity incentive plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
FAQ
What is the current stock price of Adicet Bio (ACET)?
The current stock price of Adicet Bio (ACET) is $0.91 as of December 20, 2024.
What is the market cap of Adicet Bio (ACET)?
The market cap of Adicet Bio (ACET) is approximately 72.3M.
What is Adicet Bio, Inc.?
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer.
What are the key products in Adicet Bio's pipeline?
The key products include ADI-001, a CAR T cell therapy targeting CD20 for autoimmune diseases and aggressive B cell non-Hodgkin's lymphoma, and ADI-270, an armored CAR T cell candidate targeting CD70 for renal cell carcinoma.
What recent achievements has Adicet Bio made?
Recent achievements include FDA clearance for ADI-001 in lupus nephritis, successful strategic collaborations, significant financing rounds, and promising preclinical data presentations.
How is Adicet Bio financially positioned?
Adicet Bio has a strong cash position with $247.6 million in cash and equivalents as of March 31, 2024, funding operations into the second half of 2026.
What strategic collaborations has Adicet Bio entered into?
Adicet Bio has a strategic collaboration with Regeneron Pharmaceuticals to develop engineered immune-cell therapeutics using its gamma delta T cell allogeneic platform technology.
What is the focus of Adicet Bio's research and development?
Adicet Bio's R&D focuses on creating 'off-the-shelf' gamma delta T cell therapies engineered with CARs and TCRs for cancer and autoimmune diseases.
What are ADI-001 and ADI-270?
ADI-001 is a gamma delta T cell therapy targeting CD20 for non-Hodgkin's lymphoma and autoimmune diseases, while ADI-270 targets CD70 for renal cell carcinoma and other CD70+ cancers.
What makes Adicet Bio's approach unique?
Adicet Bio utilizes gamma delta T cells with CAR and TCR engineering, providing off-the-shelf, allogeneic therapies that offer durable and effective treatments for patients.
What is the significance of the FDA's fast track designation for ADI-001?
The fast track designation for ADI-001 by the FDA facilitates the development and expedites the review process for this promising therapy targeting lupus nephritis.
Where can I find more information about Adicet Bio?
For more information, visit Adicet Bio's official website at https://www.adicetbio.com.
Adicet Bio, Inc.
Nasdaq:ACET
ACET Rankings
ACET Stock Data
72.29M
69.64M
1.59%
76.44%
4.16%
Biotechnology
Pharmaceutical Preparations
United States of America
BOSTON